av Helene Dugstad | sep 29, 2021
Scientists at University of Oslo have identified a mitochondrial enzyme, MTHFD2, as a potential therapeutic target in prostate cancer and are developing a method to inhibit the target with siRNA technology. Pre-clinical studies have shown that therapeutic silencing of...
av Helene Dugstad | sep 27, 2021
Our team at Oslo University Hospital and University of Oslo has found a potent immune regulatory microRNA harbouring a potential to treat inflammatory conditions. Osteoarthritis is a common inflammatory joint disease and the specific microRNA represents a novel...
av Mika Falck-Hansen | jan 6, 2021
BUSINESS OPPORTUNITY This new CAR T-cell can be developed to treat children and adults with B cell lymphoma. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed an engineered human albumin variant with extended in vivo half-life. This unique albumin can be used as a fusion partner to improve the pharmacokinetics of...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed a novel technology for enhanced uptake of subunit vaccines across mucosal barriers. This technology is built on an engineered human albumin variant with increased mucosal...
